Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies

Clodoveo Ferri; Vincenzo Raimondo; Laura Gragnani; Dilia Giuggioli; Lorenzo Dagna; Antonio Tavoni; Francesco Ursini; Massimo L’Andolina; Francesco Caso; Piero Ruscitti; Maurizio Caminiti; Rosario Foti; Valeria Riccieri; Serena Guiducci; Roberta Pellegrini; Elisabetta Zanatta; Giuseppe Varcasia; Domenico Olivo; Pietro Gigliotti; Giovanna Cuomo; Giuseppe Murdaca; Riccardo Cecchetti; Rossella De Angelis; Nicoletta Romeo; Francesca Ingegnoli; Franco Cozzi; Veronica Codullo; Ilaria Cavazzana; Michele Colaci; Giuseppina Abignano; Maria De Santis; Ennio Lubrano; Enrico Fusaro; Amelia Spinella; Federica Lumetti; Giacomo De Luca; Silvia Bellando-Randone; Elisa Visalli; Ylenia Dal Bosco; Giorgio Amato; Daiana Giannini; Silvia Bilia; Francesco Masini; Greta Pellegrino; Erika Pigatto; Elena Generali; Giuseppa Pagano Mariano; Giorgio Pettiti; Giovanni Zanframundo; Raffaele Brittelli; Vincenzo Aiello; Rodolfo Caminiti; Daniela Scorpiniti; Tommaso Ferrari; Corrado Campochiaro; Veronica Brusi; Micaela Fredi; Liala Moschetti; Fabio Cacciapaglia; Sabrina Rosaria Paparo; Francesca Ragusa; Valeria Mazzi; Giusy Elia; Silvia Martina Ferrari; Ilenia Di Cola; Marta Vadacca; Sebastiano Lorusso; Monica Monti; Serena Lorini; Maria Letizia Aprile; Marco Tasso; Mario Miccoli; Silvia Laura Bosello; Salvatore D’Angelo; Salvatore D'Angelo; Andrea Doria; Franco Franceschini; Riccardo Meliconi; Marco Matucci-Cerinic; Florenzo Iannone; Roberto Giacomelli; Carlo Salvarani; Anna Linda Zignego; Poupak Fallahi; Alessandro Antonelli

doi:10.2174/1381612828666220614151732

Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies

Clodoveo Ferri, Vincenzo Raimondo, Laura Gragnani, Dilia Giuggioli, Lorenzo Dagna, Antonio Tavoni, Francesco Ursini, Massimo L’Andolina, Francesco Caso, Piero Ruscitti, Maurizio Caminiti, Rosario Foti, Valeria Riccieri, Serena Guiducci, Roberta Pellegrini, Elisabetta Zanatta, Giuseppe Varcasia, Domenico Olivo, Pietro Gigliotti, Giovanna CuomoGiuseppe Murdaca, Riccardo Cecchetti, Rossella De Angelis, Nicoletta Romeo, Francesca Ingegnoli, Franco Cozzi, Veronica Codullo, Ilaria Cavazzana, Michele Colaci, Giuseppina Abignano, Maria De Santis, Ennio Lubrano, Enrico Fusaro, Amelia Spinella, Federica Lumetti, Giacomo De Luca, Silvia Bellando-Randone, Elisa Visalli, Ylenia Dal Bosco, Giorgio Amato, Daiana Giannini, Silvia Bilia, Francesco Masini, Greta Pellegrino, Erika Pigatto, Elena Generali, Giuseppa Pagano Mariano, Giorgio Pettiti, Giovanni Zanframundo, Raffaele Brittelli, Vincenzo Aiello, Rodolfo Caminiti, Daniela Scorpiniti, Tommaso Ferrari, Corrado Campochiaro, Veronica Brusi, Micaela Fredi, Liala Moschetti, Fabio Cacciapaglia, Sabrina Rosaria Paparo, Francesca Ragusa, Valeria Mazzi, Giusy Elia, Silvia Martina Ferrari, Ilenia Di Cola, Marta Vadacca, Sebastiano Lorusso, Monica Monti, Serena Lorini, Maria Letizia Aprile, Marco Tasso, Mario Miccoli, Silvia Laura Bosello, Salvatore D’Angelo, Salvatore D'Angelo, Andrea Doria, Franco Franceschini, Riccardo Meliconi, Marco Matucci-Cerinic, Florenzo Iannone, Roberto Giacomelli, Carlo Salvarani, Anna Linda Zignego, Poupak Fallahi, Alessandro Antonelli

Risultato della ricerca: Contributo in rivista › Articolo in rivista

Abstract

Objective: Autoimmune systemic diseases (ASD) represent a predisposing condition to COVID-19. Our prospective, observational multicenter telephone survey study aimed to investigate the prevalence, prognostic factors, and outcomes of COVID-19 in Italian ASD patients. Methods: The study included 3,918 ASD pts (815 M, 3103 F; mean age 59 +/- 12SD years) consecutively recruited between March 2020 and May 2021 at the 36 referral centers of COVID-19 and ASD Italian Study Group. The possible development of COVID-19 was recorded by means of a telephone survey using a standardized symptom assessment questionnaire. Results: ASD patients showed a significantly higher prevalence of COVID-19 (8.37% vs. 6.49%; p<0.0001) but a death rate statistically comparable to the Italian general population (3.65% vs. 2.95%). Among the 328 ASD patients developing COVID-19, 17% needed hospitalization, while mild-moderate manifestations were observed in 83% of cases. Moreover, 12/57 hospitalized patients died due to severe interstitial pneumonia and/or cardiovascular events; systemic sclerosis (SSc) patients showed a significantly higher COVID-19-related death rate compared to the general population (6.29% vs. 2.95%; p=0.018). Major adverse prognostic factors to develop COVID-19 were: older age, male gender, SSc, pre-existing ASD-related interstitial lung involvement, and long-term steroid treatment. Of note, patients treated with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) showed a significantly lower prevalence of COVID-19 compared to those without (3.58% vs. 46.99%; p=0.000), as well as the SSc patients treated with low dose aspirin (with 5.57% vs. without 27.84%; p=0.000). Conclusion: During the first three pandemic waves, ASD patients showed a death rate comparable to the general population despite the significantly higher prevalence of COVID-19. A significantly increased COVID-19-related mortality was recorded in only SSc patients' subgroup, possibly favored by preexisting lung fibrosis. Moreover, ongoing long-term treatment with csDMARDs in ASD might usefully contribute to the generally positive outcomes of this frail patients' population.

Lingua originale	English
pagine (da-a)	2022-2028
Numero di pagine	7
Rivista	Current Pharmaceutical Design
Volume	28
DOI	https://doi.org/10.2174/1381612828666220614151732
Stato di pubblicazione	Pubblicato - 2022

Keywords

COVID-19
DMARD
aspirin
autoimmune systemic diseases
interstitial lung involvement
steroids
systemic sclerosis
vasculitis

Accesso al documento

10.2174/1381612828666220614151732

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Ferri, C., Raimondo, V., Gragnani, L., Giuggioli, D., Dagna, L., Tavoni, A., Ursini, F., L’Andolina, M., Caso, F., Ruscitti, P., Caminiti, M., Foti, R., Riccieri, V., Guiducci, S., Pellegrini, R., Zanatta, E., Varcasia, G., Olivo, D., Gigliotti, P., ... Antonelli, A. (2022). Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies. Current Pharmaceutical Design, 28, 2022-2028. https://doi.org/10.2174/1381612828666220614151732

@article{1b5ee3fe902b4f4691310927cceff75b,

title = "Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies",

abstract = "Objective: Autoimmune systemic diseases (ASD) represent a predisposing condition to COVID-19. Our prospective, observational multicenter telephone survey study aimed to investigate the prevalence, prognostic factors, and outcomes of COVID-19 in Italian ASD patients. Methods: The study included 3,918 ASD pts (815 M, 3103 F; mean age 59 +/- 12SD years) consecutively recruited between March 2020 and May 2021 at the 36 referral centers of COVID-19 and ASD Italian Study Group. The possible development of COVID-19 was recorded by means of a telephone survey using a standardized symptom assessment questionnaire. Results: ASD patients showed a significantly higher prevalence of COVID-19 (8.37% vs. 6.49%; p<0.0001) but a death rate statistically comparable to the Italian general population (3.65% vs. 2.95%). Among the 328 ASD patients developing COVID-19, 17% needed hospitalization, while mild-moderate manifestations were observed in 83% of cases. Moreover, 12/57 hospitalized patients died due to severe interstitial pneumonia and/or cardiovascular events; systemic sclerosis (SSc) patients showed a significantly higher COVID-19-related death rate compared to the general population (6.29% vs. 2.95%; p=0.018). Major adverse prognostic factors to develop COVID-19 were: older age, male gender, SSc, pre-existing ASD-related interstitial lung involvement, and long-term steroid treatment. Of note, patients treated with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) showed a significantly lower prevalence of COVID-19 compared to those without (3.58% vs. 46.99%; p=0.000), as well as the SSc patients treated with low dose aspirin (with 5.57% vs. without 27.84%; p=0.000). Conclusion: During the first three pandemic waves, ASD patients showed a death rate comparable to the general population despite the significantly higher prevalence of COVID-19. A significantly increased COVID-19-related mortality was recorded in only SSc patients' subgroup, possibly favored by preexisting lung fibrosis. Moreover, ongoing long-term treatment with csDMARDs in ASD might usefully contribute to the generally positive outcomes of this frail patients' population.",

keywords = "COVID-19, DMARD, aspirin, autoimmune systemic diseases, interstitial lung involvement, steroids, systemic sclerosis, vasculitis, COVID-19, DMARD, aspirin, autoimmune systemic diseases, interstitial lung involvement, steroids, systemic sclerosis, vasculitis",

author = "Clodoveo Ferri and Vincenzo Raimondo and Laura Gragnani and Dilia Giuggioli and Lorenzo Dagna and Antonio Tavoni and Francesco Ursini and Massimo L{\textquoteright}Andolina and Francesco Caso and Piero Ruscitti and Maurizio Caminiti and Rosario Foti and Valeria Riccieri and Serena Guiducci and Roberta Pellegrini and Elisabetta Zanatta and Giuseppe Varcasia and Domenico Olivo and Pietro Gigliotti and Giovanna Cuomo and Giuseppe Murdaca and Riccardo Cecchetti and {De Angelis}, Rossella and Nicoletta Romeo and Francesca Ingegnoli and Franco Cozzi and Veronica Codullo and Ilaria Cavazzana and Michele Colaci and Giuseppina Abignano and {De Santis}, Maria and Ennio Lubrano and Enrico Fusaro and Amelia Spinella and Federica Lumetti and {De Luca}, Giacomo and Silvia Bellando-Randone and Elisa Visalli and {Dal Bosco}, Ylenia and Giorgio Amato and Daiana Giannini and Silvia Bilia and Francesco Masini and Greta Pellegrino and Erika Pigatto and Elena Generali and Mariano, {Giuseppa Pagano} and Giorgio Pettiti and Giovanni Zanframundo and Raffaele Brittelli and Vincenzo Aiello and Rodolfo Caminiti and Daniela Scorpiniti and Tommaso Ferrari and Corrado Campochiaro and Veronica Brusi and Micaela Fredi and Liala Moschetti and Fabio Cacciapaglia and Paparo, {Sabrina Rosaria} and Francesca Ragusa and Valeria Mazzi and Giusy Elia and Ferrari, {Silvia Martina} and {Di Cola}, Ilenia and Marta Vadacca and Sebastiano Lorusso and Monica Monti and Serena Lorini and Aprile, {Maria Letizia} and Marco Tasso and Mario Miccoli and Bosello, {Silvia Laura} and Salvatore D{\textquoteright}Angelo and Salvatore D'Angelo and Andrea Doria and Franco Franceschini and Riccardo Meliconi and Marco Matucci-Cerinic and Florenzo Iannone and Roberto Giacomelli and Carlo Salvarani and Zignego, {Anna Linda} and Poupak Fallahi and Alessandro Antonelli",

year = "2022",

doi = "10.2174/1381612828666220614151732",

language = "English",

volume = "28",

pages = "2022--2028",

journal = "Current Pharmaceutical Design",

issn = "1381-6128",

publisher = "Bentham Science Publishers BV:PO Box 7917, Exec Ste Y 26, Saif Zone Sharjah Uae:011 971 6 5571132, EMAIL: [email protected], INTERNET: http://www.bentham.org, Fax: 011 971 6 5571134",

}

Ferri, C, Raimondo, V, Gragnani, L, Giuggioli, D, Dagna, L, Tavoni, A, Ursini, F, L’Andolina, M, Caso, F, Ruscitti, P, Caminiti, M, Foti, R, Riccieri, V, Guiducci, S, Pellegrini, R, Zanatta, E, Varcasia, G, Olivo, D, Gigliotti, P, Cuomo, G, Murdaca, G, Cecchetti, R, De Angelis, R, Romeo, N, Ingegnoli, F, Cozzi, F, Codullo, V, Cavazzana, I, Colaci, M, Abignano, G, De Santis, M, Lubrano, E, Fusaro, E, Spinella, A, Lumetti, F, De Luca, G, Bellando-Randone, S, Visalli, E, Dal Bosco, Y, Amato, G, Giannini, D, Bilia, S, Masini, F, Pellegrino, G, Pigatto, E, Generali, E, Mariano, GP, Pettiti, G, Zanframundo, G, Brittelli, R, Aiello, V, Caminiti, R, Scorpiniti, D, Ferrari, T, Campochiaro, C, Brusi, V, Fredi, M, Moschetti, L, Cacciapaglia, F, Paparo, SR, Ragusa, F, Mazzi, V, Elia, G, Ferrari, SM, Di Cola, I, Vadacca, M, Lorusso, S, Monti, M, Lorini, S, Aprile, ML, Tasso, M, Miccoli, M, Bosello, SL, D’Angelo, S, D'Angelo, S, Doria, A, Franceschini, F, Meliconi, R, Matucci-Cerinic, M, Iannone, F, Giacomelli, R, Salvarani, C, Zignego, AL, Fallahi, P & Antonelli, A 2022, 'Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies', Current Pharmaceutical Design, vol. 28, pagg. 2022-2028. https://doi.org/10.2174/1381612828666220614151732

TY - JOUR

T1 - Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies

AU - Ferri, Clodoveo

AU - Raimondo, Vincenzo

AU - Gragnani, Laura

AU - Giuggioli, Dilia

AU - Dagna, Lorenzo

AU - Tavoni, Antonio

AU - Ursini, Francesco

AU - L’Andolina, Massimo

AU - Caso, Francesco

AU - Ruscitti, Piero

AU - Caminiti, Maurizio

AU - Foti, Rosario

AU - Riccieri, Valeria

AU - Guiducci, Serena

AU - Pellegrini, Roberta

AU - Zanatta, Elisabetta

AU - Varcasia, Giuseppe

AU - Olivo, Domenico

AU - Gigliotti, Pietro

AU - Cuomo, Giovanna

AU - Murdaca, Giuseppe

AU - Cecchetti, Riccardo

AU - De Angelis, Rossella

AU - Romeo, Nicoletta

AU - Ingegnoli, Francesca

AU - Cozzi, Franco

AU - Codullo, Veronica

AU - Cavazzana, Ilaria

AU - Colaci, Michele

AU - Abignano, Giuseppina

AU - De Santis, Maria

AU - Lubrano, Ennio

AU - Fusaro, Enrico

AU - Spinella, Amelia

AU - Lumetti, Federica

AU - De Luca, Giacomo

AU - Bellando-Randone, Silvia

AU - Visalli, Elisa

AU - Dal Bosco, Ylenia

AU - Amato, Giorgio

AU - Giannini, Daiana

AU - Bilia, Silvia

AU - Masini, Francesco

AU - Pellegrino, Greta

AU - Pigatto, Erika

AU - Generali, Elena

AU - Mariano, Giuseppa Pagano

AU - Pettiti, Giorgio

AU - Zanframundo, Giovanni

AU - Brittelli, Raffaele

AU - Aiello, Vincenzo

AU - Caminiti, Rodolfo

AU - Scorpiniti, Daniela

AU - Ferrari, Tommaso

AU - Campochiaro, Corrado

AU - Brusi, Veronica

AU - Fredi, Micaela

AU - Moschetti, Liala

AU - Cacciapaglia, Fabio

AU - Paparo, Sabrina Rosaria

AU - Ragusa, Francesca

AU - Mazzi, Valeria

AU - Elia, Giusy

AU - Ferrari, Silvia Martina

AU - Di Cola, Ilenia

AU - Vadacca, Marta

AU - Lorusso, Sebastiano

AU - Monti, Monica

AU - Lorini, Serena

AU - Aprile, Maria Letizia

AU - Tasso, Marco

AU - Miccoli, Mario

AU - Bosello, Silvia Laura

AU - D’Angelo, Salvatore

AU - D'Angelo, Salvatore

AU - Doria, Andrea

AU - Franceschini, Franco

AU - Meliconi, Riccardo

AU - Matucci-Cerinic, Marco

AU - Iannone, Florenzo

AU - Giacomelli, Roberto

AU - Salvarani, Carlo

AU - Zignego, Anna Linda

AU - Fallahi, Poupak

AU - Antonelli, Alessandro

PY - 2022

Y1 - 2022

N2 - Objective: Autoimmune systemic diseases (ASD) represent a predisposing condition to COVID-19. Our prospective, observational multicenter telephone survey study aimed to investigate the prevalence, prognostic factors, and outcomes of COVID-19 in Italian ASD patients. Methods: The study included 3,918 ASD pts (815 M, 3103 F; mean age 59 +/- 12SD years) consecutively recruited between March 2020 and May 2021 at the 36 referral centers of COVID-19 and ASD Italian Study Group. The possible development of COVID-19 was recorded by means of a telephone survey using a standardized symptom assessment questionnaire. Results: ASD patients showed a significantly higher prevalence of COVID-19 (8.37% vs. 6.49%; p<0.0001) but a death rate statistically comparable to the Italian general population (3.65% vs. 2.95%). Among the 328 ASD patients developing COVID-19, 17% needed hospitalization, while mild-moderate manifestations were observed in 83% of cases. Moreover, 12/57 hospitalized patients died due to severe interstitial pneumonia and/or cardiovascular events; systemic sclerosis (SSc) patients showed a significantly higher COVID-19-related death rate compared to the general population (6.29% vs. 2.95%; p=0.018). Major adverse prognostic factors to develop COVID-19 were: older age, male gender, SSc, pre-existing ASD-related interstitial lung involvement, and long-term steroid treatment. Of note, patients treated with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) showed a significantly lower prevalence of COVID-19 compared to those without (3.58% vs. 46.99%; p=0.000), as well as the SSc patients treated with low dose aspirin (with 5.57% vs. without 27.84%; p=0.000). Conclusion: During the first three pandemic waves, ASD patients showed a death rate comparable to the general population despite the significantly higher prevalence of COVID-19. A significantly increased COVID-19-related mortality was recorded in only SSc patients' subgroup, possibly favored by preexisting lung fibrosis. Moreover, ongoing long-term treatment with csDMARDs in ASD might usefully contribute to the generally positive outcomes of this frail patients' population.

AB - Objective: Autoimmune systemic diseases (ASD) represent a predisposing condition to COVID-19. Our prospective, observational multicenter telephone survey study aimed to investigate the prevalence, prognostic factors, and outcomes of COVID-19 in Italian ASD patients. Methods: The study included 3,918 ASD pts (815 M, 3103 F; mean age 59 +/- 12SD years) consecutively recruited between March 2020 and May 2021 at the 36 referral centers of COVID-19 and ASD Italian Study Group. The possible development of COVID-19 was recorded by means of a telephone survey using a standardized symptom assessment questionnaire. Results: ASD patients showed a significantly higher prevalence of COVID-19 (8.37% vs. 6.49%; p<0.0001) but a death rate statistically comparable to the Italian general population (3.65% vs. 2.95%). Among the 328 ASD patients developing COVID-19, 17% needed hospitalization, while mild-moderate manifestations were observed in 83% of cases. Moreover, 12/57 hospitalized patients died due to severe interstitial pneumonia and/or cardiovascular events; systemic sclerosis (SSc) patients showed a significantly higher COVID-19-related death rate compared to the general population (6.29% vs. 2.95%; p=0.018). Major adverse prognostic factors to develop COVID-19 were: older age, male gender, SSc, pre-existing ASD-related interstitial lung involvement, and long-term steroid treatment. Of note, patients treated with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) showed a significantly lower prevalence of COVID-19 compared to those without (3.58% vs. 46.99%; p=0.000), as well as the SSc patients treated with low dose aspirin (with 5.57% vs. without 27.84%; p=0.000). Conclusion: During the first three pandemic waves, ASD patients showed a death rate comparable to the general population despite the significantly higher prevalence of COVID-19. A significantly increased COVID-19-related mortality was recorded in only SSc patients' subgroup, possibly favored by preexisting lung fibrosis. Moreover, ongoing long-term treatment with csDMARDs in ASD might usefully contribute to the generally positive outcomes of this frail patients' population.

KW - COVID-19

KW - DMARD

KW - aspirin

KW - autoimmune systemic diseases

KW - interstitial lung involvement

KW - steroids

KW - systemic sclerosis

KW - vasculitis

KW - COVID-19

KW - DMARD

KW - aspirin

KW - autoimmune systemic diseases

KW - interstitial lung involvement

KW - steroids

KW - systemic sclerosis

KW - vasculitis

UR - http://hdl.handle.net/10807/237574

U2 - 10.2174/1381612828666220614151732

DO - 10.2174/1381612828666220614151732

M3 - Article

SN - 1381-6128

VL - 28

SP - 2022

EP - 2028

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

ER -

Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo